Vol 1, No 1 (2010)
Review paper
Published online: 2010-02-04

open access

Page views 503
Article views/downloads 7908
Get Citation

Connect on Social Media

Connect on Social Media

Practical recommendations on the management of myelodysplastic syndromes with special emphasis on the use of lenalidomide in del(5q)

Krzysztof Warzocha
Hematologia 2010;1(1):71-79.


The last decade witnessed significant improvement of myelodysplastic syndrome (MDS) therapy results. This was due to more objective criteria for histopathological diagnosis according to World Health Organization (WHO) classification and risk stratification of International Prognostic System Score (IPSS). Treatment strategies are tailored based on the therapeutic goals within each classification and prognostic risk groups and consist of the best supportive care with or without less or more intense cytoreduction. This was allowed due to the emergence of new therapies, including lenalidomide in patients with IPSS low or intermediate-low risk MDS with del(5q), and demethylating agents (azacitidine, decitabine) in the treatment of patients with intermediate-high and high risk or refractory MDS.

Article available in PDF format

View PDF (Polish) Download PDF file

Hematology in Clinical Practice